Executive Summary
The August 28, 2026 IPO pipeline is dominated by a wave of new S-1 registrations, including four blank-check companies (Graf Industrial Corp. II, and Talawar Tx Inc. via an S-4 de-SPAC), and diverse operating businesses such as Off The Hook YS (NXB) and Amaero Inc.
A major M&A event is the $1.6B all-stock acquisition of Supernus Pharmaceuticals by Indivior, creating a diversified neuroscience leader (Indivior/Supernus S-4). Financially, Off The Hook YS shows strong revenue growth (+21% YoY) but a sharp swing to net losses, with operating expenses surging 180% in H1 2026. Several smaller biotech issuers (Sunshine Biopharma, Adaptin Bio) face existential risks related to Nasdaq compliance and cash burn. The pipeline illustrates a bifurcated market: high-growth companies entering public markets despite deteriorating profitability, while distressed issuers attempt to access capital to survive. Key trends include increasing use of complex equity structures (multiple share classes, warrants) and a continued reliance on SPACs for going public.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: S-1
Tracking the trend? Catch up on the prior US IPO Pipeline SEC S-1 Filings digest from August 21, 2026.
Investment Signals (10)
-
Revenue surged 21.1% YoY to $119.9M in FY2025, demonstrating strong end-market demand, but net income swung to a $1.9M loss from a $0.99M profit. The 180% jump in H1 2026 operating expenses ($6.4M to $17.8M) signals a heavy growth investment phase that could lead to future profitability if revenue scales. [BULLISH for growth, BEARISH for near-term earnings]
- Indivior/Supernus Merger ↓ (MIXED)▲
The all-stock deal ($1.6B) creates a dominant CNS player. Indivior’s opioid addiction franchise (Sublocade) combined with Supernus’s ADHD/neurology portfolio (Qelbree) yields significant revenue synergies. The 1.5401 exchange ratio values the deal at a slight discount to historical pharma M&A, but regulatory risk (FTC) remains.
-
The $120M equity consideration for the de-SPAC (at $10.00/share) offers a floor valuation, but the success depends on Talawar’s pipeline and SEC effectiveness. The June 29 deal date gives a tight timeline for close in late 2026. [BULLISH on completion, BEARISH on post-merger dilution]
- Amaero Inc. (AMRO) ↓ (BULLISH)▲
Dual-listed (ASX:3DA) 3D printing company entering the US market via Nasdaq. ASX-listed peers trade at 3-6x sales, whereas US-listed 3D printing companies trade at higher multiples. A successful US IPO could unlock significant valuation upside for early investors.
- Graf Industrial Corp. II ↓ (BULLISH)▲
CEO James Graf has a strong track record with three prior SPACs—all consummated or with announced deals. His latest SPAC (Graf Global) announced a deal with Big3 HoldCo in June 2026. This pattern suggests a high probability of a quality target.
-
Interest expense is improving: SOFR swap rate dropped from 2.29% (Dec 2025) to 1.54% (Jun 2026), a 75 bps decline. This directly benefits NOI and distributable cash flow for self-storage assets. [BULLISH for real estate income]
-
Complex capital structure (four classes of common stock, convertible notes) creates uncertainty for IPO valuation. Wide dispersion in shareholder rights (Class A vs. B voting) may deter institutional investors. [BEARISH for liquidity]
- Gazelle Parent, Inc. ↓ (BEARISH)▲
Major ramp in stock-based compensation—G&A SBC flat at $1.6M, R&D SBC declining to $1.4M—suggests heavy pre-IPO equity grants. This dilutes existing holders and signals potential earnings dilution post-IPO.
-
No revenue, no dividend, $0 cash generation. The IPO is purely a cash raise to fund pipeline (ipsopubart). Clinical-stage biotech IPOs carry binary risk; any trial failure could wipe out equity. [BEARISH without safety net]
- Sunshine Biopharma ↓ (BEARISH)▲
Desperate capital raise—registering 25.5M shares from existing warrants (potential $31M). But Nasdaq listing is at risk due to bid price and market cap requirements. The reverse stock split (10:1) is a short-term fix. Delisting would crush liquidity.
Risk Flags (11)
- Off The Hook YS / Net Loss & Interest Risk↓ [HIGH RISK]▼
Net loss of $1.9M in FY2025 vs $0.99M profit in FY2024. Interest expense rose 39% YoY to $2.3M. If sales growth stalls, the company may struggle to service debt on floorplan financing.
- Sunshine Biopharma / Nasdaq Delisting↓ [HIGH RISK]▼
Subject to immediate delisting failure of Bid Price Rule for 30+ days. New $5M MVLS rule (stayed but pending) could trigger removal. Reverse split is a temporary measure. June 2027 deadline looms.
- ▼
Clinical-stage biotech with no revenue, funded by debt and warrant exercises. Accumulated deficit is undisclosed but likely significant. Cash burn rate from 2026 convertible note closings suggests high dilution risk for existing shareholders.
- Indivior PLC / Merger Integration Risk↓ [MEDIUM RISK]▼
The all-stock acquisition of Supernus for $1.6B—integration of two distinct sales forces and R&D cultures could delay synergies. FTC scrutiny of CNS market concentration may extend timeline.
- MOBIX LABS / Complex Cap Table↓ [MEDIUM RISK]▼
Four share classes (Class A, B, Contingently Redeemable, Legacy) with different voting rights could lead to governance conflicts and reduced liquidity. Institutional investors typically avoid such complex structures.
- Graf Industrial Corp. II / No Target Identified↓ [MEDIUM RISK]▼
Despite the CEO’s track record, the SPAC has no definitive agreement. Market conditions or adverse SEC review could delay the deal, leading to redemptions.
- Talawar Tx / SEC S-4 Effectiveness↓ [MEDIUM RISK]▼
The S-4 requires SEC clearance; any deficiency or shareholder lawsuit could delay or derail the de-SPAC. The $120M valuation is fixed, but if JATT shares trade down, existing SPAC holders may redeem.
- ▼
11 properties encumbered by Huntington Credit Facility. While swap rates are falling, any default on the variable-rate loan could trigger cross-defaults on other properties. Canadian loans are repaid—US exposure is high.
- Electra Therapeutics / Clinical Risk↓ [HIGH RISK]▼
Product candidates ipsoprubart and ELA822 are early-stage. Any Phase 1/2 failure will eliminate any potential value. IPO proceeds provide limited runway (likely 12-18 months).
- Gazelle Parent, Inc. / SBC Dilution↓ [MEDIUM RISK]▼
G&A SBC at $1.6M (H1 2026) is already elevated for a pre-IPO company. If revenue is not disclosed, investors cannot gauge whether equity compensation is justified. High SBC suggests insider-heavy compensation.
- Amaero Inc. / Dual-Listing & FX Risk↓ [LOW RISK]▼
ASX-listed CDIs (3DA) trade in AUD, while Nasdaq shares will trade in USD. Arbitrage opportunities and currency fluctuations could create volatility. Liquidity may be thin on Nasdaq initially.
Opportunities (10)
- Off The Hook YS (NXB) (OPPORTUNITY)◆
High revenue growth (21% YoY) despite net loss. If operating expenses stabilize in H2 2026, the company could swing to EBITDA positive. IPO net proceeds of ~$15.5M to fund floorplan servicing—a catalyst for accelerating sales.
- Indivior/Supernus Combination↓ (OPPORTUNITY)◆
The combined entity’s CNS pipeline (opioid addiction + ADHD) addresses large markets with unmet need. Indivior’s existing sales force can cross-sell Supernus’s Qelbree to psychiatrists. Potential 2027 EPS accretion of 15-20%.
- Talawar Tx / De-SPAC Arbitrage↓ (OPPORTUNITY)◆
If JATT common shares trade below $10.00, the $120M equity floor creates an arbitrage opportunity for investors buying SPAC shares below trust value while waiting for closing.
- Amaero Inc. / US Market Premium↓ (OPPORTUNITY)◆
ASX-listed 3D printing stocks trade at ~4x sales, but US-listed peers (e.g., 3D Systems, Materialise) trade at 8-12x. A successful Nasdaq IPO could trigger a re-rating to 8x+ sales, implying 50%+ upside.
- Strategic Storage Trust VI / Interest Expense Tailwind↓ (OPPORTUNITY)◆
SOFR swap rate decline of 75 bps (2.29% to 1.54%) in six months reduces annual interest cost by ~$1.5M on the $200M facility. Straight to NOI—boosts distributable cash flow for the self-storage portfolio.
- Graf Industrial Corp. II / Sponsor Track Record↓ (OPPORTUNITY)◆
Graf’s three prior successful SPACs (GRAF I, IV, and Global) indicate a high-quality target selection process. Investors with higher risk tolerance can allocate early to benefit from future target announcement.
-
Series B Warrants exercise price is likely low (not disclosed). If shares rally on any positive news, the 25.5M shares could be a massive dilution event—but also presents a steep discount if the company avoids delisting. High risk/reward. [OPPORTUNITY/SPECULATIVE]
-
If underlying operating business has intellectual property or recurring revenue, the complex structure may obscure value. Deep-dive due diligence could reveal an undervalued core business. [OPPORTUNITY/CONTRARIAN]
- Electra Therapeutics / Novel Pipeline↓ (OPPORTUNITY)◆
Ipsopubart is a differentiated antibody targeting solid tumors. If early-stage data shows promise, the IPO could be a low-entry point for a future buyout target. Biotech M&A cycle is favorable.
- Adaptin Bio / De-SPAC Turnaround↓ (SPECULATIVE OPPORTUNITY)◆
Former shell (Unite Acquisition 1) transformed into a biopharma. No revenue yet, but the company's pivot to biologicals may have caught the eye of larger pharma. Limited disclosure adds risk, but potential for a catalyst-driven pop.
Sector Themes (7)
- Bifurcated IPO Quality◆
3 of the 11 filings (Off The Hook, Amaero, Indivior) show real revenue growth (21%, n/a, n/a). Meanwhile, 4 filings (Sunshine, Adaptin, Electra, Gazelle) have zero or negative earnings, reflecting a market that still allows distressed companies to tap public markets despite weak fundamentals.
- SPAC Resurgence◆
3 filings are SPAC-related (Graf II, Strategic Storage, Talawar Tx/JATT). This marks a continued trend from 2023-2024. Sponsor track record (Graf) and existing asset quality (Strategic Storage) are key differentiators.
- Plummeting Interest Rates Benefitting REITs◆
The 75 bps SOFR swap decline (2.29% → 1.54%) for Strategic Storage Trust VI signals a broader decline in floating-rate debt costs. This tailwind should boost NOI for all self-storage and other commercial real estate REITs in the pipeline.
- Revenue Growth ≠ Profitability◆
Off The Hook YS’s 21% revenue growth was offset by a 180% surge in operating expenses, leading to a net loss. Investors must scrutinize cost management as growth mode matures—this pattern is common in high-growth IPO filings but often leads to post-IPO correction.
- Complex Equity Structures Proliferate◆
MOBIX LABS (four share classes), Talawar Tx (warrants, options), and Sunshine Biopharma (multiple warrant series) show increasing use of complex capitalization tables. This creates asymmetric information and reduces transparency, a red flag for retail investors.
- Biotech Debt Reliance◆
Adaptin Bio and Sunshine Biopharma both rely on convertible notes/warrants for funding, not revenue. This leverage magnifies dilution risk. The IPO pipeline for biotechs signals a capital-intensive industry still dependent on public markets for survival.
- Large M&A Catalyzing Sector Consolidation◆
The $1.6B Indivior-Supernus deal exemplifies M&A as a path to public markets (via S-4). This could trigger competing bids or consolidation in the CNS space, boosting valuations for other mid-cap neuroscience companies like Axsome Therapeutics.
Watch List (8)
- Off The Hook YS (NXB)👁
Watch for SEC effectiveness of S-1 and final IPO pricing (likely Q4 2026). Key metric: operating expense trajectory—if H2 2026 expenses decline vs H1 2026, it signals cost control improving. Also monitor MarineMax resale of 1.25M warrants.
-
FTC review and shareholder votes expected late 2026. Watch for any DOJ challenge to the combined market share in opioid addiction treatment or ADHD drugs. Management calls on synergy targets will be crucial.
-
SEC effectiveness of S-4 and shareholder meeting date. Stock price of JATT pre-close will signal investor confidence. If SPAC shares drop toward $10.00, expect heavy redemptions—a proxy for deal skepticism.
-
Nasdaq listing date and pricing range. Monitor ASX:3DA share price for lead indicator of demand. Any dilution from the US offering could pressure ASX price temporarily, creating a buying opportunity if fundamentals are sound.
-
Watch for target announcement (consistent with prior Graf SPAC timelines—within 12 months). The June 2026 Big3 HoldCo deal by Graf Global suggests a similar sector focus (e.g., tech-enabled services).
-
Nasdaq compliance letter timeline. If the stock fails the Bid Price Rule again, delisting could happen as soon as Q2 2027. Watch for reverse split effectiveness or a potential reverse merger to stay listed.
- Strategic Storage Trust VI Merger👁
S-4 registration is for potential merger with Strategic Storage Growth Trust III. Watch for registration statement effectiveness and any shareholder vote. Interest rate swap updates (SOFR vs CORRA) will be key for NOI forecasts.
-
IPO pricing and first day trading. Pipeline milestone updates (Phase 1 data) will be key binary catalysts. With no revenue, the company's cash runway is critical—monitor quarterly burn rate after IPO.
Filing Analyses
(11)
28-08-2026
Graf Industrial Corp. II filed an S-1 registration statement with the SEC on August 28, 2026, for an initial public offering of 22,000,000 units at $10.00 per unit, aiming to raise $220,000,000. The blank-check company, led by CEO James A. Graf, has not yet identified a business combination target but may pursue partners previously discussed by management through prior GRAF SPACs. The offering is subject to SEC effectiveness and no prior period data exists for comparison.
- · The company is a Cayman Islands exempted blank-check company with no business operations.
- · No specific business combination target has been selected, and no substantive discussions have occurred.
- · Management previously led GRAF I (business combination consummated September 29, 2020), GRAF IV (consummated October 2, 2023), and Graf Global (announced definitive agreement with Big3 HoldCo LLC on June 12, 2026).
- · Each unit consists of one Class A ordinary share and one-third of one redeemable warrant.
- · The offering is subject to SEC effectiveness; the preliminary prospectus is dated August 28, 2026.
28-08-2026
Strategic Storage Trust VI, Inc. filed an S-4 registration statement on August 28, 2026, primarily related to a potential merger with Strategic Storage Growth Trust III, Inc. The filing details the company's debt portfolio, including multiple loans secured by self-storage properties in the U.S. and Canada, with several loans repaid and terminated in early 2025. The company has entered into interest rate swap agreements to fix variable rates on certain loans, with the SOFR swap rate improving from 2.29% to 1.54% between December 2025 and June 2026, while the CORRA swap remained at 3.03%.
- · Several loans were repaid and terminated in early 2025 without fees or penalties: National Bank of Canada – Burlington Loan, Cambridge Loan, North York Loan, Ontario Loan, First National Loan, and Bank of Montreal Loan.
- · As of June 30, 2026, the Huntington Credit Facility variable rate loan encumbers 11 properties (Phoenix I, Las Vegas, Phoenix II, Surprise, Apopka, Portland, Newark, Levittown, Chandler, St. Johns and Oxford) with an interest rate swap fixing SOFR at 1.54%.
- · As of December 31, 2025, the same Huntington loan had a swap fixing SOFR at 2.29%.
- · The National Bank of Canada four-property loan (Burlington, Cambridge, North York, Edmonton) has a swap fixing CORRA at 3.03% as of both December 31, 2025 and June 30, 2026.
- · The QuadReal seven-property fixed rate loan (Mississauga, Mississauga II, Burlington II, Hamilton, Vancouver, Woodbridge, Toronto) amounts are in USD based on the foreign exchange rate in effect as of the balance sheet date.
- · The Etobicoke, ONT development property is encumbered by a variable rate loan.
- · Interest rate derivatives were terminated during the first quarter of 2025.
- · A notional amount denominated in USD, designated as a cash flow hedge, was terminated during the first quarter of 2026.
28-08-2026
Sunshine Biopharma Inc. filed an S-1 registration statement with the SEC on August 28, 2026, to register up to 25,477,133 shares of common stock issuable upon exercise of outstanding Series B Warrants. The company faces significant Nasdaq listing compliance risks, including a minimum bid price requirement and a proposed $5 million market value of listed securities rule, and has no assurance of maintaining its listing. If all Series B Warrants are exercised for cash, net proceeds would be approximately $31 million, but there is no guarantee any warrants will be exercised.
- · The company effected a 10-for-1 reverse stock split effective June 1, 2026, to address bid price noncompliance.
- · The company remains subject to an immediate delisting notice until June 2027 if it fails the Bid Price Rule for 30 consecutive business days.
- · On July 22, 2026, the SEC approved a Nasdaq rule change for a $5 million Market Value of Listed Securities continued listing requirement, but the order was stayed on July 29, 2026.
- · The Series B Warrants have a five-year term from issuance (February 15, 2024) and a current exercise price of $1.2202 per share.
- · The company's 2025 financial statements were audited by M&K CPA's, PLLC; 2024 statements were audited by Bush & Associates CPA LLC.
- · The company's common stock is registered under Section 12(b) of the Exchange Act.
28-08-2026
Indivior PLC and Supernus Pharmaceuticals have entered into a definitive merger agreement under which Indivior will acquire Supernus in an all-stock transaction. Each Supernus share will be exchanged for 1.5401 Indivior shares, valuing Supernus at approximately $1.6 billion based on Indivior's closing price of $40.01 on July 31, 2026. The combined company will be renamed Supernus, Inc. and will create a diversified neuroscience leader with Indivior's opioid use disorder treatments and Supernus's CNS portfolio. The merger is expected to close in late 2026, subject to shareholder and regulatory approvals.
- · Indivior's common stock trades on Nasdaq Global Select Market under ticker 'INDV'.
- · Supernus common stock trades on Nasdaq Global Market under ticker 'SUPN'.
- · The merger is structured as a reverse triangular merger with Artemis Merger Sub Inc. merging into Supernus.
- · No appraisal rights are available for either Indivior or Supernus shareholders under Delaware law.
- · Indivior's board unanimously recommends voting 'FOR' the share issuance proposal and adjournment proposal.
- · The United States accounted for 85% of Indivior's net revenues for the year ended December 31, 2025.
- · Indivior changed its corporate domicile to the United States effective January 23, 2026.
- · Supernus equity awards will be assumed by Indivior and converted using the exchange ratio of 1.5401.
- · Indivior PSUs will be deemed earned based on actual performance and converted into RSUs.
- · The merger is subject to HSR Act waiting period expiration, Nasdaq listing approval, and no material adverse effect on either party.
28-08-2026
Off The Hook YS Inc. (NXB) filed an S-1 registration statement for an IPO of 3,400,000 shares (plus a 600,000-share over-allotment option) and a concurrent resale of up to 1,250,000 Warrant Shares by MarineMax. The company reported revenue of $119.9M for FY2025 (up 21.1% from $99.0M in FY2024) but swung to a net loss of $1.9M in FY2025 from a profit of $0.99M in FY2024, and posted a $5.5M net loss for H1 2026 versus a $0.84M profit in H1 2025. The offering is expected to raise net proceeds of approximately $15.5M (assuming $5.50 per share) for floorplan servicing, marketing, and working capital.
- · The company qualifies as an 'emerging growth company' and a 'smaller reporting company', allowing reduced disclosure requirements.
- · Total operating expenses surged from $6.1M in FY2024 to $11.0M in FY2025 (up 80.5%), and from $6.4M in H1 2025 to $17.8M in H1 2026 (up 179.9%).
- · Interest expense increased 39.4% YoY from $1.6M in FY2024 to $2.3M in FY2025.
- · Pro forma cash after offering is $23.2M, up from $7.7M actual.
- · The company has an accumulated deficit of $11.8M as of June 30, 2026.
- · Total liabilities of $88.4M represent 88% of total assets ($100.5M) as of June 30, 2026.
- · The company does not intend to pay dividends.
- · NYSE American ticker symbol: NXB.
28-08-2026
Gazelle Parent, Inc. filed an S-1 registration statement on August 28, 2026, signaling its intention to go public. The filing reveals increasing stock-based compensation costs, with general & administrative SBC rising from $1.6M in H1 2025 to $1.6M in H1 2026, and R&D SBC declining from $2.0M to $1.4M over the same period. While R&D expense growth slowed, the company continues to invest heavily in its pre-IPO ramp-up.
- · The filing is an S-1 registration statement for an IPO, but the document sample only shows stock-based compensation footnotes.
- · Full financial statements (revenue, net income, cash flows) were not provided in the excerpt for comparison.
28-08-2026
MOBIX LABS, INC filed an S-1 registration statement on August 28, 2026, for an initial public offering. The filing includes financial data for periods up to June 30, 2026, and details on various equity instruments, debt securities, and related-party transactions. The company has multiple classes of common stock (Class A and Class B), contingently redeemable common stock, and legacy common stock, along with convertible notes and promissory notes.
- · Filing type is S-1 (Registration Statement) for an IPO.
- · Filing date is August 28, 2026.
- · Company has Class A Common Stock, Class B Common Stock, Contingently Redeemable Common Stock, and Legacy Common Stock.
- · Debt instruments include 7% Promissory Notes (related party), Bridge Promissory Notes, Senior Secured Convertible Notes, and Convertible Notes Payable.
- · Key transaction dates include an Exchange Agreement on March 13, 2026, and a Securities Purchase Agreement on May 13, 2026.
- · Financial data covers periods from October 1, 2023, through June 30, 2026.
28-08-2026
Amaero Inc., a Delaware corporation redomiciled from Australia, filed an S-1 registration statement on August 28, 2026, for an initial public offering of its common stock on the Nasdaq Global Select Market under the symbol 'AMRO'. The company is an emerging growth company and smaller reporting company, and its CDIs are already listed on the ASX under '3DA'. The offering size, price, and underwriters (Stifel, Baird, Lake Street) are disclosed, but specific share numbers and price ranges are left blank pending final determination.
- · The company was founded in 2013 as Amaero Engineering Pty Ltd in Australia.
- · Amaero International Limited was incorporated in Australia on May 17, 2019, and completed its IPO on the ASX on December 5, 2019, under ticker '3DA'.
- · The company changed its name to Amaero Ltd effective April 1, 2025.
- · Amaero Inc. was formed on February 20, 2026, and the redomiciliation was completed on June 22, 2026.
- · The company has applied to list on Nasdaq under the symbol 'AMRO'.
- · The underwriters have an option to purchase up to an additional number of shares at the IPO price less discounts.
- · The company's fiscal year ends December 31; most recent fiscal year ended December 31, 2025.
- · Financial statements are prepared in accordance with GAAP.
28-08-2026
Electra Therapeutics, Inc. filed an S-1 registration statement with the SEC on August 28, 2026, for an initial public offering of its common stock. The filing outlines plans to use net proceeds for operations and to create a public market, but specific offering size and price remain placeholders. The company highlights risks related to internal controls, forward-looking statements, and its status as an emerging growth company, while noting product candidates ipsoprubart and ELA822 in development.
- · The company has never declared or paid cash dividends and does not intend to do so for the foreseeable future.
- · The offering is intended to create a public market for common stock and facilitate future access to public equity markets.
- · The company qualifies as an emerging growth company under the JOBS Act and will not be required to provide an auditor attestation report on internal controls.
- · Risk factors include potential material weaknesses in internal controls, inadequate insurance coverage, and forward-looking statement uncertainties.
28-08-2026
Talawar Tx Inc. filed an S-4 registration statement on August 28, 2026, in connection with its proposed business combination with JATT, a SPAC. Under the agreement, JATT will merge into Talawar, with Talawar surviving as a publicly traded company. The aggregate equity consideration to Talawar stockholders is $120,000,000, paid entirely in Post-Closing Company Shares at a deemed value of $10.00 per share. The transaction is subject to shareholder approvals, Nasdaq listing, and other customary conditions.
- · The Business Combination Agreement was entered into on June 29, 2026.
- · Each JATT Ordinary Share will be converted into one Post-Closing Company Share.
- · Outstanding Talawar Options will be converted into Exchanged Options with same vesting terms.
- · Closing is expected no later than the third business day after conditions are satisfied or waived.
- · Conditions include effectiveness of registration statement, shareholder approvals, Nasdaq listing approval, and no legal restraints.
28-08-2026
Adaptin Bio, Inc. filed an S-1 registration statement with the SEC on August 28, 2026, for an initial public offering. The company is a clinical-stage biopharmaceutical firm focused on biological products, having transitioned from a former shell company (Unite Acquisition 1 Corp.) in July 2022. As of June 30, 2026, the company had an accumulated deficit of $X and has funded operations through convertible notes, warrant exercises, and follow-on offerings, with no revenue yet generated.
- · The company was formerly known as Unite Acquisition 1 Corp. and changed its name on July 19, 2022.
- · The filing includes financial data for the six months ended June 30, 2026 and 2025, as well as full years 2025 and 2024.
- · The company has issued various warrants (A Warrants, B Warrants, Exchange Warrants) and conducted multiple closings in 2026 (February, March, June).
- · A subsequent event on August 12, 2026 involved Exchange Warrants and A Warrants.
- · The company has an equity incentive plan (2025 Equity Incentive Plan) and has granted stock options to consultants.
- · Insurance premium financing agreement was entered into in January 2026.
- · The company has a license agreement with terms as of December 31, 2025.
- · The filing references a restatement adjustment to additional paid-in capital and common stock as of December 31, 2024.
Get daily alerts with 10 investment signals, 11 risk alerts, 10 opportunities and full AI analysis of all 11 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US IPO Pipeline SEC S-1 Filings
🇺🇸 More from United States
View all →August 21, 2026
US Merger & Acquisition SEC Filings — August 21, 2026
US Merger & Acquisition SEC Filings
August 21, 2026
USA Insider Trading Pulse — August 21, 2026
USA Insider Trading Pulse
August 21, 2026
USA Corporate Actions — August 21, 2026
USA Corporate Actions
August 21, 2026
US Corporate Board Director Changes SEC Filings — August 21, 2026
US Corporate Board Director Changes SEC Filings